Navigation Links
Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study of HGS-ETR1 -

ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today reported that clinical and preclinical evidence continues to emerge demonstrating that its TRAIL receptor antibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), have significant potential for use in the treatment of a broad range of cancers.

"We believe that HGS-ETR1 and HGS-ETR2 could offer novel, highly targeted therapeutic options that may prove useful in the treatment of a number of cancers," said Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research - Oncology, HGS. "We note with pride that the Journal of Clinical Oncology, one of the field's most prestigious peer-reviewed publications, chose to publish the first human study of HGS-ETR1 earlier this month with an accompanying editorial - and, last week at AACR 2007, approximately 1500 cancer scientists and researchers attended our oral presentation of research results to date."

Results in the Journal of Clinical Oncology

The results of the first Phase 1 clinical trial of mapatumumab (HGS-ETR1) appeared in the April 10 issue of the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology (ASCO). These results in 49 patients demonstrated that mapatumumab could be administered safely and repetitively to patients with advanced solid malignancies. The authors concluded that the absence of severe toxicities, and mapatumumab's ability to achieve blood levels consistent with antitumor activity in laboratory models, warrant further study of mapatumumab as a single agent and in combination with chemotherapy in a broad array of tumors.

Based on the initial Phase 1 results, along with extensive preclinical data, HGS initiated a broad clinical development program that included Phase 2 trials of HGS-ETR1 as a sin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:4/24/2015)... PHILADELPHIA , April 24, 2015  Lannett Company, ... has amended and increased its five-year revolving credit facility ... includes an accordion feature that will allow the company ... an additional $30.0 million, subject to securing additional commitments ... date of the credit facility remains December 18, 2018. ...
(Date:4/23/2015)... 24, 2015  AbbVie (NYSE: ABBV ) has ... has accepted its New Drug Application (NDA) and granted ... antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin ... with chronic genotype 4 (GT4) hepatitis C virus (HCV) ... interferon-free therapy being evaluated by the FDA for patients ...
(Date:4/23/2015)... Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that ... on Thursday, May 7, 2015, after the close of ... audio webcast immediately following the announcement at 4:30 p.m. ... results and provide a business and financial update. ... via the Investors & Media section of the Jazz ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 2
... 2010 TechniScan, Inc. (OTC Bulletin Board: ... development and commercialization of an automated breast ultrasound imaging system, ... TechniScan entered into amendments with each note holder, effective as ... its entire portfolio of secured convertible promissory notes from October ...
... 8, 2010 Arstasis is pleased to announce that ... Registry Evaluating Closure Following Access with the Arstasis One ... anticipated to enroll up to 500 patients in at ... is to observe the clinical safety and effectiveness of ...
Cached Medicine Technology:TechniScan, Inc. Announces Restructuring of Convertible Debt 2Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years 2Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years 3
(Date:4/25/2015)... 25, 2015 The impact of the ... the excitement of the public and is likely to ... of May and June. From March 21st to ... tradition of "Special Prayers." More than 600 people participated ... Special Prayers and have reported intense experiences that they ...
(Date:4/25/2015)... April 25, 2015 The URO CENTER of ... has been chosen by the New York Academy of Medicine ... medicine in the field of Urology. , Dr. Ferdinand Valentine, ... speciality, Genito-Urinary diseases. He was a man of rare ... of urology. Not only did he devote his life ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Bird B Gone, ... residential applications now offers a complete line of bird control ... poultry farms. , New Flu Strains Threaten Pacific, Central and ... USDA post , a number of highly pathogenic avian ... The disease is often spread when wild birds enter poultry ...
(Date:4/24/2015)... Foothill Ranch, California (PRWEB) April 24, 2015 ... that has a wide range of capabilities and services ... etc. , Ryadon's Quantity Discount Program will be ... ) as follows: , Order 4-19: Receive 10% discount ... Can Benefit by Using the Drawer Slides Products, ...
(Date:4/24/2015)... The 1975 have had an intense past ... to theaters, festivals and TV performances. Now that they’ve settled ... label, Dirty Hit Records, to provide clean drinking water to ... Cadence & Cause website, this four-piece has graciously ... a signed photo card. Entries from this sweepstakes ...
Breaking Medicine News(10 mins):Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... Today, PARI Respiratory,Equipment presented a comparative ... their in-vitro performance and delivery,efficiency of budesonide ... in-vitro study show that the LC Sprint,Reusable ... an average,of 4.9 minutes, and had the ...
... 28 For World Psoriasis,Day, Oct. 29, the ... Web site, http://www.psoriasis.org, and sign up ... disease of the,immune system that appears on the ... Day, awareness activities will,occur all over the world ...
... you know that one in six men will,be diagnosed ... occurs,every 2.5 minutes and a man dies from prostate ... first., Listen to this report from Philips Norelco ... audio, text, graphics and,photos for free and unrestricted use ...
... Iraq, Afghanistan who sought medical care were victims , , ... the challenges facing women in the military, a new ... Iraq and Afghanistan veterans seeking VA medical care reported ... reported sexual trauma, such as rape and threatening sexual ...
... The Family Planning,Council was recently awarded three grants ... a total of $3 million. These grants will,support state-of-the-art ... Natural Family Planning as a method of birth control ... a model program to,provide family planning services to men., ...
... . , Montreal, October 28, 2008 - Patients 80 ... perfectly able to withstand open-heart surgery, according to the latest ... Centre (MUHC). His findings were presented this morning in Toronto ... be a reason for doctors to rule out the possibility ...
Cached Medicine News:Health News:PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008 2Health News:National Psoriasis Foundation Seeks 10,000 Americans to Support Psoriasis Research for World Psoriasis Day 2Health News:National Psoriasis Foundation Seeks 10,000 Americans to Support Psoriasis Research for World Psoriasis Day 3Health News:Sexual Trauma Haunts Many Female Vets 2Health News:Sexual Trauma Haunts Many Female Vets 3Health News:Local Organization Receives Multi-Million Dollar Grants for Natural Family Planning, HIV Testing and Family Planning Services for Men 2
... High-Throughput (HTP) Protein Electrophoresis ... integrated pre-cast gel system ... protein analysis. It consists ... E-Base™ integrated power device, ...
... E-Holder™ Platform is designed with a spring-loaded ... and E-Gel® 48 gel cassettes stay firmly ... reproducible placement and loading from one gel ... adjustments to the robot loading software. In ...
... routine agarose gel electrophoresis into an automated, ... This bufferless, pre-cast system is ideal for ... digests, and more. Fully automated, robot-compatible, and ... 96 system makes your high-throughput screening assignments ...
... Injection molded chambers are seamless eliminating the ... The Primo tanks have temperature resistant gel ... to pour you gels. For added user friendliness, ... a UV fluorescent rule. The Primo Gel ...
Medicine Products: